Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol’s Boerner To Succeed CEO Caforio With Launch Execution In The Spotlight

Executive Summary

Giovanni Caforio will step down as CEO of Bristol Myer Squibb effective 1 November, with chief commercialization officer Boerner primed to succeed him.

You may also be interested in...

BMS Revs R&D Engine To Advance 10 New Drug Candidates Annually

Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.

BMS Speeding Six More Programs Into Late-Stage R&D

With big losses of exclusivity later in this decade, Bristol is looking to boost the number of products in its portfolio by 2030 even beyond the $35bn-plus in new revenue it already expects to bring in.

BMS Resets 2023 Guidance With Bigger Than Expected Drop In Revlimid Sales

Bristol saw a big jump in free Revlimid and Pomalyst provided through patient support programs. It does not expect the issue to persist in 2024, but now expects 2023 revenue to decline rather than grow.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts